Understanding the pathology and mechanisms of type I diabetic bone loss

Journal of Cellular Biochemistry

Volumn 102, Issue 6, 2007, Pages 1343-1357

  McCabe, Laura R ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University   (United States)

Author keywords

Bone; Density; Diabetes; Fat; Insulin; Marrow; Metabolism; Osteoblast

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; INSULIN RECEPTOR;

BONE DENSITY; BONE MARROW; CELL DEATH; DISEASE PREDISPOSITION; GENE REPRESSION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEX DIFFERENCE;

ANIMALS; BONE DISEASES, METABOLIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OSTEOPOROSIS;

ANIMALIA;

EID: 36849045166     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21573     Document Type: Review

References (161)

1. Accili D, Taylor SI. 1991. Targeted inactivation of the insulin receptor gene in mouse 3T3-L1 fibroblasts via homologous recombination. Proc Natl Acad Sci USA 88:4708-4712.
2. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD, Jose PA, Taylor SI, Westphal H. 1996. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12:106-109.
3. Ahdjoudj S, Lasmoles F, Holy X, Zerath E, Marie PJ. 2002. Transforming growth factor beta2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J Bone Miner Res 17:668-677.
4. Ahdjoudj S, Fromigue O, Marie PJ. 2004. Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: Potential implication in the treatment of age-related bone loss. Histol Histopathol 19:151-157.
5. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. 2004. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855.
6. Alexopoulou O, Jamart J, Devogelaer JP, Brichard S, de Nayer P, Buysschaert M. 2006. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 32:453-458.
7. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. 2005. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235.
8. Auwerx J, Dequeker J, Bouillon R, Geusens P, Nijs J. 1988. Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus. Diabetes 37:8-12.
9. Balint E, Szabo P, Marshall CF, Sprague SM. 2001. Glucose-induced inhibition of in vitro bone mineralization. Bone 28:21-28.
10. Bechtold S, Dirlenbach I, Raile K, Noelle V, Bonfig W, Schwarz HP. 2006. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: Data using peripheral quantitative computed tomography. Pediatrics 118:e627-e634.
11. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. 2005. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102:3324-3329.
12. Bodine PV, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, Scrimo MJ, Bhat RA, Stauffer B, Green J, Stein GS, Lian JB, Komm BS. 2005. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96:1212-1230.
13. Bonfanti R, Mora S, Prinster C, Bognetti E, Meschi F, Puzzovio M, Proverbio MC, Chiumello G. 1997. Bone modeling indexes at onset and during the first year of follow-Up in insulin-dependent diabetic children. Calcif Tissue Int 60:397-400.
14. Botolin S, McCabe LR. 2006a. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411-424.
15. Botolin S, McCabe LR. 2006b. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 209:967-976.
16. Botolin S, McCabe L. 2007a. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 148:198-205.
17. Botolin S, McCabe LR. 2007b. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 148:198-205.
18. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. 2005. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146:3622-3631.
19. Bouillon R. 1991. Diabetic bone disease [editorial]. Calcif Tissue Int 49:155-160.
20. Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E. 1995. Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80:1194-1202.
21. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. 2005. Acidosis Inhibits Bone Formation by Osteoblasts In Vitro by Preventing Mineralization. Calcif Tissue Int 77:167-174.
22. Brownlee M, Vlassara H, Cerami A. 1984. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101:527-537.
23. Bucala R, Model P, Cerami A. 1984. Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 81:105-109.
24. Buysschaert M, Cauwe F, Jamart J, Brichant C, De Coster P, Magnan A, Donckier J. 1992. Proximal femur density in type 1 and 2 diabetic patients. Diabetes Metab 18:32-37.
25. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. 1999. L-arginine transport in retinas from streptozotocin diabetic rats: Correlation with the level of IL-1 beta and NO synthase activity. Vision Res 39:3817-3823.
26. Ceolotto G, Gallo A, Miola M, Sartori M, Trevisan R, Del Prato S, Semplicini A, Avogaro A. 1999. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 48:1316-1322.
27. Chaturvedi N, Fuller JH, Taskinen MR. 2001. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 24:2071-2077.
28. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. 2003. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278:45969-45977.
29. Christeff N, Homo-Delarche F, Thobie N, Durant S, Dardenne M, Nunez EA. 1994. Free fatty acid profiles in the non-obese diabetic (NOD) mouse: Basal serum levels and effects of endocrine manipulation. Prostaglandins Leukot Essent Fatty Acids 51:125-131.
30. Cinti S, Eberbach S, Castellucci M, Accili D. 1998. Lack of insulin receptors affects the formation of white adipose tissue in mice. A morphometric and ultrastructural analysis. Diabetologia 41:171-177.
31. Clark RG. 2004. Recombinant human insulin-like growth factor I (IGF-I): Risks and benefits of normalizing blood IGF-I concentrations. Horm Res 62 (Suppl 1):93-100.
32. Cloos C, Wahl P, Hasslacher C, Traber L, Kistner M, Jurkuhn K, Schmidt-Gayk H. 1998. Urinary glycosylated, free and total pyridinoline and free and total deoxypyridinoline in diabetes mellitus. Clin Endocrinol (Oxf) 48:317-323.
33. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J. 2004. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 5:1007-1012.
34. Cullen P, von Eckardstein A, Souris S, Schulte H, Assmann G. 1999. Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1:189-198.
35. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. 2004. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483:79-93.
36. Dai XM, Zong XH, Akhter MP, Stanley ER. 2004. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 19:1441-1451.
37. Diascro DD Jr, Vogel RL, Johnson TE, Witherup KM, Pitzenberger SM, Rutledge SJ, Prescott DJ, Rodan GA, Schmidt A. 1998. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res 13:96-106.
38. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM, Mi QS. 2006. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 340:1091-1097.
39. Duque G. 2003. Will reducing adopogenesis in bone increase bone mass?: PPARgamma2 as a key target in the treatment of age-related bone loss. Drug News Perspect 16:341-346.
40. Entingh-Pearsall A, Kahn CR. 2004. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 279:38016-38024.
41. Epstein S, Takizawa M, Stein B, Katz IA, Joffe II, Romero DF, Liang XG, Li M, Ke HZ, Jee WS. 1994. Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat. J Bone Miner Res 9:557-566.
42. Faulkner MS, Chao WH, Kamath SK, Quinn L, Fritschi C, Maggiore JA, Williams RH, Reynolds RD. 2006. Total homocysteine, diet, and lipid profiles in type 1 and type 2 diabetic and nondiabetic adolescents. J Cardiovasc Nurs 21:47-55.
43. Ferre P. 2004. The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl 1):S43-S50.
44. Folk JW, Starr AJ, Early JS. 1999. Early wound complications of operative treatment of calcaneus fractures: Analysis of 190 fractures. J Orthop Trauma 13:369-372.
45. Ford ES, Mokdad AH, Giles WH, Mensah GA. 2003. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107:2185-2189.
46. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 1995. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803-812.
47. Forsen L, Meyer HE, Midthjell K, Edna TH. 1999. Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag Health Survey. Diabetologia 42:920-925.
48. Fulzele K, Digirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. 2007. Disruption of the IGF-1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 282:25649-25658.
49. Gabbay KH. 1973. The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836.
50. Giglio MJ, Giannunzio G, Olmedo D, Guglielmotti MB. 2000. Histomorphometric study of bone healing around laminar implants in experimental diabetes. Implant Dent 9:143-149.
51. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. 2006. Playing with bone and fat. J Cell Biochem 98:251-266.
52. Goodman WG, Hori MT. 1984. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 33:825-831.
53. Gunczler P, Lanes R, Paz-Martinez V, Martins R, Esaa S, Colmenares V, Weisinger JR. 1998. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 11:413-419.
54. Hadjadj S, Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, Ebran J, Marre M. 2004. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 30:43-51.
55. Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. 2006. Bone mineral density of both genders in Type 1 diabetes according to bone composition. J Diabetes Complications 20:302-307.
56. Haffner SM, Bauer RL. 1993. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 42:735-738.
57. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. 2000. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345.
58. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Vaananen HK. 2002. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71:20-25.
59. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. 2005. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20:994-1001.
60. Hanaki K, Becker DJ, Arslanian SA. 1999. Leptin before and after insulin therapy in children with new-onset type 1 diabetes. J Clin Endocrinol Metab 84:1524-1526.
61. Herrero S, Calvo OM, Garcia-Moreno C, Martin E, San Roman JI, Martin M, Garcia-Talavera JR, Calvo JJ, del Pino-Montes J. 1998. Low bone density with normal bone turnover in ovariectomized and streptozotocin-induced diabetic rats. Calcif Tissue Int 62:260-265.
62. Herskind AM, Christensen K, Norgaard-Andersen K, Andersen JF. 1992. Diabetes mellitus and healing of closed fractures. Diabete Metab 18:63-64.
63. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. 2007. Osteoporosis in Patients with Diabetes Mellitus. J Bone Miner Res 22:1317-1328.
64. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074-1078.
65. Horcajada-Molteni MN, Chanteranne B, Lebecque P, Davicco MJ, Coxam V, Young A, Barlet JP. 2001. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 16:958-965.
66. Hough S, Avioli LV, Bergfeld MA, Fallon MD, Slatopolsky E, Teitelbaum SL. 1981. Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology 108:2228-2234.
67. Hunt JV, Smith CC, Wolff SP. 1990. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39:1420-1424.
68. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, Thompson TJ, Narayan KM, Gregg EW. 2004. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol 160:531-539.
69. Inaba M, Nishizawa Y, Shioi A, Morii H. 1997. Importance of sustained high glucose condition in the development of diabetic osteopenia: Possible involvement of the polyol pathway. Osteoporos Int 7:S209-S212.
70. Irwin R, Lin HV, Motyl KJ, McCabe LR. 2006. Normal bone density obtained in the absence of insulin receptor expression in bone*. Endocrinology 147:5760-5767.
71. Irwin R, LaPres JJ, Kinser S, McCabe LR. 2007. Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype. J Cell Biochem 100:762-772.
72. Jahr H, van Driel M, van Osch GJ, Weinans H, van Leeuwen JP. 2005. Identification of acid-sensing ion channels in bone. Biochem Biophys Res Commun 337:349-354.
73. Jehle PM, Jehle DR, Mohan S, Bohm BO. 1998. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol 159:297-306.
74. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. 1996. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740.
75. Kajkenova O, Lecka-Czernik B, Gubrij I, Hauser SP, Takahashi K, Parfitt AM, Jilka RL, Manolagas SC, Lipschitz DA. 1997. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12:1772-1779.
76. Karaguzel G, Ozdem S, Boz A, Bircan I, Akcurin S. 2006. Leptin levels and body composition in children and adolescents with type 1 diabetes. Clin Biochem 39:788-793.
77. Karsenty G. 2006. Convergence between bone and energy homeostases: Leptin regulation of bone mass. Cell Metab 4:341-348.
78. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. 1996. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11:931-937.
79. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
80. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. 2000. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295-303.
81. Kindblom JM, Gevers EF, Skrtic SM, Lindberg MK, Gothe S, Tornell J, Vennstrom B, Ohlsson C. 2005. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 36:607-616.
82. Knouff C, Auwerx J. 2004. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: Lessons from genetics and pharmacology. Endocr Rev 25:899-918.
83. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK. 2005. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596.
84. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. 1995. Bone loss and bone turnover in diabetes. Diabetes 44:775-782.
85. Kream BE, Smith MD, Canalis E, Raisz LG. 1985. Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology 116:296-302.
86. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. 2005. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20:1647-1658.
87. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T. 2002. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55:65-85.
88. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM. 2000. Blockade of RAGE suppresses periodontitis- associated bone loss in diabetic mice. J Clin Invest 105:1117-1124.
89. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. 2006. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38:74-84.
90. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. 1999. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357-371.
91. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. 2002. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384.
92. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. 2007. Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469.
93. Levin ME, Boisseau VC, Avioli LV. 1976. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294:241-245.
94. Levy JR, Murray E, Manolagas S, Olefsky JM. 1986. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 119:1786-1792.
95. Lian JB, Stein GS, Stein JL, van Wijnen AJ. 1998. Osteocalcin gene promoter: Unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem Suppl 30-31:62-72.
96. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, FoIz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
97. Locatto ME, Abranzon H, Caferra D, Fernandez MC, Alloatti R, Puche RC. 1993. Growth and development of bone mass in untreated alloxan diabetic rats. Effects of collagen glycosylation and parathyroid activity on bone turnover. Bone Miner 23:129-144.
98. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, Pardo MD, Gonzalez AG, Luna JD, Requena ME, Diosdado MA. 2001. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 7:346-351.
99. Lu H, Kraut D, Gerstenfeld LC, Graves DT. 2003. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 144:346-352.
100. Luna R, Garcia-Mayor RV, Lage M, Andrade MA, Barreiro J, Pombo M, Dieguez C, Casanueva FF. 1999. High serum leptin levels in children with type 1 diabetes mellitus: Contribution of age, BMI, pubertal development and metabolic status. Clin Endocrinol (Oxf) 51:603-610.
101. Lunt H, Florkowski CM, Cundy T, Kendall D, Brown LJ, Elliot JR, Wells JE, Turner JG. 1998. A population-based study of bone mineral density in women with long-standing type 1 (insulin dependent) diabetes. Diabetes Res Clin Pract 40:31-38.
102. Maahs DM, Wadwa RP, McFann K, Nadeau K, Williams MR, Eckel RH, Klingensmith GJ. 2007. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J Pediatr 150:146-150, 150, e1-e2.
103. Martin LM, McCabe LR. 2007. Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol 128:125-133.
104. Martin A, de Vittoris R, David V, Moraes R, Begeot M, Lafage-Proust MH, Alexandre C, Vico L, Thomas T. 2005. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 146:3652-3659.
105. Martos-Moreno GA, Barrios V, Soriano-Guillen L, Argente J. 2006. Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur J Endocrinol 155:757-761.
106. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 6:483-495.
107. McCarthy AD, Etcheverry SB, Bruzzone L, Cortizo AM. 1997. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem 170:43-51.
108. McCarthy AD, Etcheverry SB, Cortizo AM. 2001. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: Role in osteoblast development. Acta Diabetol 38:113-122.
109. McCracken M, Lemons JE, Rahemtulla F, Prince CW, Feldman D. 2000. Bone response to titanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants 15:345-354.
110. Meunier P, Aaron J, Edouard C, Vignon G. 1971. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop 80:147-154.
111. Meyer HE, Tverdal A, Falch JA. 1993. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 137:1203-1211.
112. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. 2005. Elevated hip fracture risk in type 1 diabetic patients: A population-based cohort study in Sweden. Diabetes Care 28:2850-2855.
113. Mishima N, Sahara N, Shirakawa M, Ozawa H. 2002. Effect of streptozotocin-induced diabetes mellitus on alveolar bone: deposition in the rat. Arch Oral Biol 47:843-849.
114. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. 2004. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3:379-389.
115. Munoz-Torres M, Jodar E, Escobar-Jimenez F, Lopez-Ibarra PJ, Luna JD. 1996. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 58:316-319.
116. Nakae J, Kido Y, Accili D. 2001. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22:818-835.
117. Niu T, Rosen CJ. 2005. The insulin-like growth factor-I gene and osteoporosis: A critical appraisal. Gene 361:38-56.
118. Nuttall ME, Gimble JM. 2004. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4:290-294.
119. Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M, Demer LL. 1999. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 14:2067-2078.
120. Pascual J, Argente J, Lopez MB, Munoz M, Martinez G, Vazquez MA, Jodar E, Perez-Cano R, Hawkins F. 1998. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 62:31-35.
121. Phan TC, Xu J, Zheng MH. 2004. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol Histopathol 19:1325-1344.
122. Picard F, Auwerx J. 2002. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-197.
123. Pighin D, Karabatas L, Pastorale C, Dascal E, Carbone C, Chicco A, Lombardo YB, Basabe JC. 2005. Role of lipids in the early developmental stages of experimental immune diabetes induced by multiple low-dose streptozotocin. J Appl Physiol 98:1064-1069.
124. Rosen CJ. 2004. Insulin-like growth factor I and bone mineral density: Experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 18:423-435.
125. Rosen CJ, Bouxsein ML. 2006. Mechanisms of disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35-43.
126. Rosen ED, Spiegelman BM. 2000. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16:145-171.
127. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML, Horowitz M. 2004. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 35:1046-1058.
128. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. 2004. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406.
129. Sasaki T, Kaneko H, Ramamurthy NS, Golub LM. 1991. Tetracycline administration restores osteoblast structure and function during experimental diabetes. Anat Rec 231:25-34.
130. Sasano Y, Zhu JX, Tsubota M, Takahashi I, Onodera K, Mizoguchi I, Kagayama M. 2002. Gene expression of MMP8 and MMP13 during embryonic development of bone and cartilage in the rat mandible and hind limb. J Histochem Cytochem 50:325-332.
131. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR. 2001. Older women with diabetes have an increased risk of fracture: A prospective study. J Clin Endocrinol Metab 86:32-38.
132. Shefi-Friedman L, Wertheimer E, Shen S, Bak A, Accili D, Sampson SR. 2001. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice. Am J Physiol Endocrinol Metab 281:E16-E24.
133. Shyng YC, Devlin H, Sloan P. 2001. The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. Int J Oral Maxillofac Surg 30:70-74.
134. Siqueira JT, Cavalher-Machado SC, Arana-Chavez VE, Sannomiya P. 2003. Bone formation around titanium implants in the rat tibia: Role of insulin. Implant Dent 12:242-251.
135. Strotmeyer ES, Cauley JA, Orchard TJ, Steenkiste AR, Dorman JS. 2006. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 29:306-311.
136. Takeshita F, Iyama S, Ayukawa Y, Kido MA, Murai K, Suetsugu T. 1997. The effects of diabetes on the interface between hydroxyapatite implants and bone in rat tibia. J Periodontol 68:180-185.
137. Thomas DM, Maher F, Rogers SD, Best JD. 1996. Expression and regulation by insulin of GLUT 3 in UMR106-01, a clonal rat osteosarcoma cell line. Biochem Biophys Res Commun 218:789-793.
138. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. 1999. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630-1638.
139. Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, Cockrell GE, Skinner RA, Hogue WR, Carver AA, Fowlkes JL, Aronson J, Lumpkin CK, Jr. 2005. Bone formation is impaired in a model of type 1 diabetes. Diabetes 54:2875-2881.
140. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. 2001. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46-50.
141. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T. 1999. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196-1200.
142. Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. 2002. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 58:266-272.
143. Verhaeghe J, van Herck E, Visser WJ, Suiker AM, Thomasset M, Einhorn TA, Faierman E, Bouillon R. 1990. Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 39:477-482.
144. Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R, Bouillon R. 1992. The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol 134:485-492.
145. Verhaeghe J, Thomsen JS, van Bree R, van Herck E, Bouillon R, Mosekilde L. 2000. Effects of exercise and disuse on bone remodeling, bone mass, and biomechanical competence in spontaneously diabetic female rats. Bone 27:249-256.
146. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. 2002. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693-698.
147. Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. 2005. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 28:1051-1056.
148. Waud CE, Marks SC, Jr, Lew R, Baran DT. 1994. Bone mineral density in the femur and lumbar vertebrae decreases after twelve weeks of diabetes in spontaneously diabetic-prone BB/Worcester rats. Calcif Tissue Int 54:237-240.
149. Weidman SW, Ragland JB, Fisher JN, Jr, Kitabchi AE, Sabesin SM. 1982. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: Evidence for a change in high density lipoprotein composition during treatment. J Lipid Res 23:171-182.
150. White CB, Turner NS, Lee GC, Haidukewych GJ. 2003. Open ankle fractures in patients with diabetes mellitus. Clin Orthop 414:37-44.
151. Winchester SK, Selvamurugan N, D'Alonzo RC, Partridge NC. 2000. Developmental regulation of collagenase-3 mRNA in normal, differentiating osteoblasts through the activator protein-1 and the runt domain binding sites. J Biol Chem 275:23310-23318.
152. Winocour PH, Durrington PN, Ishola M, Anderson DC. 1986. Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet 1:1176-1178.
153. Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR, Turk J. 1991. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 87:31-38.
154. Wolff SP, Dean RT. 1987. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 245:243-250.
155. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. 2000. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 275:1873-1877.
156. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. 2001. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 15:257-259.
157. Zayzafoon M, Stell C, Irwin R, McCabe LR. 2000. Extracellular glucose influences osteoblast differentiation and c-Jun expression. J Cell Biochem 79:301-310.
158. Zayzafoon M, Botolin S, McCabe LR. 2002. P38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose. J Biol Chem 277:37212-37218.
159. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. 2002a. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012.
160. Zhang W, Lu D, Kawazu S, Komeda K, Takeuchi T. 2002b. Adenoviral insulin gene therapy prolongs survival of IDDM model BB rats by improving hyperlipidemia. Horm Metab Res 34:577-582.
161. Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW. 2007. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640-1646.